Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $197.73 million
- Book Value:
- Revenue TTM:
- $5.64 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Absci Corp had its IPO on 2021-07-22 under the ticker symbol ABSI.
The company operates in the Healthcare sector and Biotechnology industry. Absci Corp has a staff strength of 211 employees.
Shares of Absci Corp opened at $1.72 at the start of the last trading session i.e. 2023-03-28.
The stocks traded within a range of $1.61 - $1.75, and closed at $1.63.
This is a -5.78% slip from the previous day's closing price.
A total volume of 235,394 shares were traded at the close of the day’s session.
In the last one week, shares of Absci Corp have increased by +2.84%.
Absci Corp's Key Ratios
Absci Corp has a market cap of $197.73 million, indicating a price to book ratio of 0.8264 and a price to sales ratio of 42.7421.
In the last 12-months Absci Corp’s revenue was $5.64 million with a gross profit of $-39804000 and an EBITDA of $-99703000. The EBITDA ratio measures Absci Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Absci Corp’s operating margin was -1983.57% while its return on assets stood at -17.74% with a return of equity of -32.48%.
In Q3, Absci Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 53.9%.
Absci Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Absci Corp’s profitability.
Absci Corp stock is trading at a EV to sales ratio of 14.6935 and a EV to EBITDA ratio of -0.8411. Its price to sales ratio in the trailing 12-months stood at 42.7421.
Absci Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $339.39 million
- Total Liabilities
- $30.03 million
- Operating Cash Flow
- Capital Expenditure
- $4.87 million
- Dividend Payout Ratio
Absci Corp ended 2023 with $339.39 million in total assets and $0 in total liabilities. Its intangible assets were valued at $339.39 million while shareholder equity stood at $292.94 million.
Absci Corp ended 2023 with $756000.00 in deferred long-term liabilities, $30.03 million in other current liabilities, 9000.00 in common stock, $-276458000.00 in retained earnings and $21.34 million in goodwill. Its cash balance stood at $107.32 million and cash and short-term investments were $181.31 million. The company’s total short-term debt was $6,510,000 while long-term debt stood at $6.52 million.
Absci Corp’s total current assets stands at $201.38 million while long-term investments were $0 and short-term investments were $73.99 million. Its net receivables were $210000.00 compared to accounts payable of $1.86 million and inventory worth $0.
In 2023, Absci Corp's operating cash flow was $-78723000.00 while its capital expenditure stood at $4.87 million.
Comparatively, Absci Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Absci Corp stock is currently trading at $1.63 per share. It touched a 52-week high of $9.38 and a 52-week low of $9.38. Analysts tracking the stock have a 12-month average target price of $12.
Its 50-day moving average was $2.44 and 200-day moving average was $3.01 The short ratio stood at 7.35 indicating a short percent outstanding of 0%.
Around 3198.9% of the company’s stock are held by insiders while 4478.9% are held by institutions.
Frequently Asked Questions About Absci Corp
Similar Industry Stocks (Biotechnology)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.